Adaptative Radiotherapy to Decrease Xerostomia in Oropharynx Carcinoma (ARTOME)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

132 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-07-05

Study Completion Date

2020-12-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Standard treatment for oropharynx cancer is radiotherapy by intensity modulation with only one planification before treatment. Adaptative radiotherapy integrates one or several planifications during treatment radiotherapy in order to take into account anatomic modifications that occurs.

Adaptative radiotherapy is very expensive, complex and is consuming human resources as well as equipment.

ARTIX study (NCT01874587) entitled "Phase III trial testing the benefit of intensity-modulated radiotherapy with weekly replanifications versus intensity modulated radiotherapy with only one planification in locally advanced oropharynx carcinoma for decreasing xerostomia" is completed and clinical data from this study are used to analyse if xerostomia is decreased when adaptative radiotherapy is used.

ARTOME study will assess cost-efficiency and cost utility between standard treatment (one pretherapeutic planification) and experimental treatment (weekly replanifications during treatment). Clinical data from ARTIX study will be used for ARTOME study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Adaptative Radiotherapy to Decrease Xerostomia in Oropharynx Carcinoma

NCT01874587

Oropharynx Cancer

COMPLETED PHASE3

Adaptive RadioTherapy for OroPharynx Cancer

NCT04901234

Oropharynx Cancer Radiotherapy; Complications Radiotherapy Side Effect +2 more

RECRUITING PHASE2

Adaptive, Image-guided, Intensity-modulated Radiotherapy for Head and Neck Cancer in the Reduced Volumes of Elective Neck

NCT01287390

Primary Non-operated Squamous Cell Carcinoma of Oral Cavity Primary Non-operated Squamous Cell Carcinoma of Oropharynx Primary Non-operated Squamous Cell Carcinoma of Hypopharynx +1 more

COMPLETED PHASE2

Phase I-II Study on Treatment of Advanced Oropharynx Cancer in Elderly Population by Intensity Modulated Radiotherapy With Treatment Volume Reduction and Combination Chemotherapy

NCT01709006

Head and Neck Cancer

TERMINATED NA

Comparison of Adaptive Dose Painting by Numbers With Standard Radiotherapy for Head and Neck Cancer.

NCT01341535

Primary Non-operated Squamous Cell Carcinoma of Oral Cavity Primary Non-operated Squamous Cell Carcinoma of Oropharynx Primary Non-operated Squamous Cell Carcinoma of Hypopharynx +1 more

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Oropharynx Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Locally advanced non-metastatic carcinoma of the oropharynx limited to T3 and T4 (whatever the N) and N2-N3 (whatever the T)(AJCC stage III-IV)
* Age ≥ 18 years and ≤ 75 years
* Performance status (WHO ≤ 2)
* Renal, hepatic and cardiovascular functions allowing systemic treatment administration
* Adapted stomatologic care
* Signed informed consent form
* Membership or beneficiary of a national insurance scheme

Exclusion Criteria

* Both parotids totally included in the target volume
* Stages T1 or T2 with positive node disease N1
* Neoadjuvant chemotherapy
* Exereses of primitive tumor and/or nodes
* History of other cancer within 5 years (except for basocellular epithelioma and cervical)
* Previous neck radiotherapy
* Platinum salts, 5FluoroUracile (5FU) agents or cetuximab chemotherapy
* Unstable diseases (cardiovascular, renal, pulmonary, systemic lupus or sclerodermia) incompatible with study participation
* Patient participating in other therapeutic trial with experimental drug, 30 days before the inclusion.
* Patient already recruited in another biomedical research ( non interventional study is authorized)
* Pregnant or breast feeding patients
* Patient deprived of liberty, under tutorship, guardianship or placed under judicial protection
* Patient is deemed incapable of giving informed consent
* Patients who, for family, social, geographic or psychological reasons, cannot be adequately followed up and/or are incapable of undergoing regular controls.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No